

Merck - IMPROVE IT update - Appears trending favorably

https://marketpublishers.com/r/M9BD0695312EN.html

Date: March 2012

Pages: 1

Price: US\$ 90.00 (Single User License)

ID: M9BD0695312EN

Abstracts

Today, Merck announced that the Data Safety Monitoring Board has given a go-ahead signal to the IMPROVE-IT after it conducted a pre-specified second interim efficacy analysis of the study (completion of 75% of the events). The DSMB will review the data again in the next nine months. We see the go-ahead signal as positive, as it is reassuring of the safety profile of Vytorin. Futility is not a pre-decided criterion for early discontinuation of the trial, hence in that context the decision of DSMB to review the data in the next nine months may be indicative of their expectation that the trial would reach statistical significance by then. The company has also indicated that the projected completion of IMPROVE IT by 2013 may change.



Contents

COMPANIES MENTIONED

MERCK



I would like to order

Product name: Merck - IMPROVE IT update - Appears trending favorably

Product link: https://marketpublishers.com/r/M9BD0695312EN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/M9BD0695312EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970